FDA Targeting Execs With Criminal Charges For Adulterated/Misbranded Goods
This article was originally published in The Rose Sheet
Executive Summary
FDA increasingly will prosecute corporate officers in response to criticism over the agency's handling of violations of the Federal Food, Drug & Cosmetic Act in recent years
You may also be interested in...
J&J Faces Possible Criminal Liability As Post-Recall Overhaul Continues
FDA's drug center referred its review of Johnson & Johnson's manufacturing operations to the Office of Criminal Investigations, which will determine whether there is criminal liability in the quality control lapses that led to extensive recalls of OTC drugs
FDA Plays Misdemeanor Card In Adulterated Supplement Prosecution
FDA's Office of Criminal Investigations assists in prosecuting the maker of "all-natural" sexual enhancement drugs, an action in line with its strategy to seek more misdemeanor charges against violative food and drug firms
Former Purdue Execs Fight Exclusion From Gov't Programs After OxyContin Case
The three former Purdue Pharma executives who pled guilty to misbranding OxyContin are battling the government for the ability to work in the health care sector. They have sued HHS for barring them from participation in government health programs for 12 years